Lipid metabolism in Alzheimer's disease

+ 作者地址

  • 参考文献
  • 相关文章
  • 统计

[2] Korade Z;Kenworthy AK .Lipid rafts, cholesterol, and the brain.[J].Neuropharmacology,2008(8):1265-1273.

[4] Mattson MP .Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis.[J].Biochimica et Biophysica Acta. Molecular and cell biology of Lipids,2010(8):878-886.

[5] Jana A;Pahan K .Fibrillar amyloid-beta-activated human astroglia kill primary human neurons via neutral sphingomyelinase: implications for Alzheimer's disease.[J].The Journal of Neuroscience: The Official Journal of the Society for Neuroscience,2010(38):12676-12689.

[6] Sanchez-Mejia RO;Newman JW;Toh S;Yu GQ;Zhou Y;Halabisky B;Cisse M;Scearce-Levie K;Cheng IH;Gan L;Palop JJ;Bonventre JV;Mucke L .Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease.[J].Nature neuroscience,2008(11):1311-1318.

[7] Esposito G;Liow JS;Greenstein D;Hallett M;Eckelman WC;Rapoport SI .Imaging Neuroinflammation in Alzheimer's Disease with Radiolabeled Arachidonic Acid and PET.[J].The Journal of Nuclear Medicine,2008(9):1414-1421.

[8] Shevchenko A;Simons K .Lipidomics: coming to grips with lipid diversity.[J].Nature reviews: molecular cell biology,2010(8):593-598.

[9] van Meer G .Cellular lipidomics[J].EMBO Journal,2005(18):3159-3165.

[10] Yetukuri L;Ekroos K;Vidal-Puig A;Oresic M .Informatics and computational strategies for the study of lipids[J].Molecular bioSystems,2008(2):121-127.

[13] Fester L;Zhou L;Butow A;Huber C;von Lossow R;Prange Kiel J;Jarry H;Rune GM .Cholesterol-promoted synaptogenesis requires the conversion of cholesterol to estradiol in the hippocampus.[J].Hippocampus,2009(8):692-705.

[14] Christian Goritz;Daniela H. Mauch;Frank W. Pfrieger .Multiple mechanisms mediate cholesterol-induced synaptogenesis in a CNS neuron[J].Molecular and cellular neurosciences,2005(2):190-201.

[21] Linetti A;Fratangeli A;Taverna .Cholesterol reduction impairs exocytosis of synaptic vesicles.[J].Journal of Cell Science,2010(4):595-605.

[22] Liu Q;Trotter J;Zhang J;Peters MM;Cheng H;Bao J;Han X;Weeber EJ;Bu G .Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration.[J].The Journal of Neuroscience: The Official Journal of the Society for Neuroscience,2010(50):17068-17078.

[23] Liu Q;Zerbinatti CV;Zhang J;Hoe HS;Wang B;Cole SL;Herz J;Muglia L;Bu G .Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1.[J].Neuron,2007(1):66-78.

[24] Moneek Madra;Stephen L Sturley .Niemann-Pick type C pathogenesis and treatment: from statins to sugars[J].Clinical lipidology,2010(3):387-395.

[25] Block RC;Beck CA;Shoulson I .Altered Cholesterol and Fatty Acid Metabolism in Huntington Disease.[J].Journal of clinical lipidology,2010(1):17-23.

[26] Di Paolo G;Kim TW .Linking lipids to Alzheimer's disease: cholesterol and beyond.[J].Nature reviews neuroscience,2011(5):284-296.

[27] Wang Q;Yan J;Chen X;Li J;Yang Y;Weng J;Deng C;Yenari MA .Statins: multiple neuroprotective mechanisms in neurodegenerative diseases.[J].Experimental Neurology,2011(1):27-34.

[28] Frisardi V;Panza F;Seripa D;Farooqui T;Farooqui AA .Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer's disease pathology.[J].Progress in Lipid Research: An International Journal,2011(4):313-330.

[30] Bazan NG .Lipid signaling in neural plasticity, brain repair, and neuroprotection.[J].Molecular Neurobiology,2005(1):89-103.

[31] Han X;Holtzman DM;McKeel DW Jr .Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry.[J].Journal of Neurochemistry: Offical Journal of the International Society for Neurochemistry,2001(4):1168-1180.

[36] Kanfer,JN;Sorrentino,G;Sitar,DS .Phospholipases as mediators of amyloid beta peptide neurotoxicity: an early event contributing to neurodegeneration characteristic of Alzheimer's disease.[J].Neuroscience Letters,1998(2):93-96.

[39] Huanling Yu;Yanxia Bi;Weiwei Ma;Lingling He;Linhong Yuan;Jinfang Feng;Rong Xiao * .Long-term effects of high lipid and high energy diet on serum lipid, brain fatty acid composition, and memory and learning ability in mice[J].International journal of developmental neuroscience: the official journal of the International Society for Developmental Neuroscience,2010(3):271-276.

[40] Ochoa JJ;Pamplona R;Ramirez Tortosa MC;Granados Principal S;Perez Lopez P;Naudi A;Portero Otin M;Lopez Frias M;Battino M;Quiles JL .Age-related changes in brain mitochondrial DNA deletion and oxidative stress are differentially modulated by dietary fat type and coenzyme Q.[J].Free Radical Biology and Medicine: The Official Journal of the Oxygen Society,2011(9):1053-1064.

[44] Herz J;Bock HH .Lipoprotein receptors in the nervous system.[J].Annual Review of Biochemistry,2002(0):405-434.

[46] Fryer JD;DeMattos RB;McCormick LM;O'Dell MA;Spinner ML;Bales KR;Paul SM;Sullivan PM;Parsadanian M;Bu GJ .The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice[J].The Journal of biological chemistry,2005(27):25754-25759.

[47] Lamsa R;Helisalmi S;Herukka SK;Tapiola T;Pirttila T;Vepsalainen S;Hiltunen M;Soininen H .Genetic study evaluating LDLR polymorphisms and Alzheimer's disease.[J].Neurobiology of Aging: Experimental and Clinical Research,2008(6):848-855.

[48] Zou F;Gopalraj RK;Lok J;Zhu H;Ling IF;Simpson JF;Tucker HM;Kelly JF;Younkin SG;Dickson DW;Petersen RC;Graff-Radford NR;Bennett DA;Crook JE;Younkin SG;Estus S .Sex-dependent association of a common low-density lipoprotein receptor polymorphism with RNA splicing efficiency in the brain and Alzheimer's disease.[J].Human Molecular Genetics,2008(7):929-935.

[49] Cao D;Fukuchi K;Wan H;Kim H;Li L .Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice.[J].Neurobiology of Aging: Experimental and Clinical Research,2006(11):1632-1643.

[50] Kim J;Castellano JM;Jiang .Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance.[J].Neuron,2009(5):632-644.

[51] Bu,G .Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy.[J].Nature Reviews. Neuroscience,2009(5):333-344.

[52] Zerbinatti CV;Wozniak DF;Cirrito J;Cam JA;Osaka H;Bales KR .Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein[J].Proceedings of the National Academy of Sciences of the United States of America,2004(4):1075-1080.

[54] Rapp A;Gmeiner B;Huttinger M .Implication of apoE isoforms in cholesterol metabolism by primary rat hippocampal neurons and astrocytes[J].Biochimie,2006(5):473-483.

[55] Fagan AM;Bu G;Sun Y;Daugherty A;Holtzman DM .Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein.[J].The Journal of biological chemistry,1996(47):30121-30125.

[57] Schmitz G;Langmann T;Heimerl S .Role of ABCG1 and other ABCG family members in lipid metabolism.[J].Journal of Lipid Research,2001(10):1513-1520.

[58] Dean M;Hamon Y;Chimini G .The human ATP-binding cassette (ABC) transporter superfamily.[J].Journal of Lipid Research,2001(7):1007-1017.

[59] Schmitz G;Kaminski WE;Orso E .ABC transporters in cellular lipid trafficking.[J].Current opinion in lipidology,2000(5):493-501.

[60] Puglielli L;Tanzi RE;Kovacs DM .Alzheimer's disease: the cholesterol connection.[J].Nature neuroscience,2003(4):345-351.

[63] Gelissen IC;Harris M;Rye KA;Quinn C;Brown AJ;Kockx M;Cartland S;Packianathan M;Kritharides L;Jessup W .ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I.[J].Arteriosclerosis, Thrombosis, and Vascular Biology,2006(3):534-540.

[64] Vaughan AM;Oram JF .ABCA1 and ABCG1 or ABCG4 act sequentially to remove cellular cholesterol and generate cholesterol-rich HDL[J].Journal of Lipid Research,2006(11):2433-2443.

[67] Karten B;Campenot RB;Vance DE;Vance JE .Expression of ABCG1, but not ABCA1, correlates with cholesterol release by cerebellar astroglia.[J].The Journal of biological chemistry,2006(7):4049-4057.

[73] Grehan,S;Tse,E;Taylor,JM .Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain.[J].The journal of neuroscience (Online),2001(3):812-822.

[76] Bertram L;McQueen MB;Mullin K;Blacker D;Tanzi RE .Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database[J].Nature Genetics,2007(1):17-23.

[77] Roses AD .Apolipoprotein E alleles as risk factors in Alzheimer's disease.[J].Annual Review of Medicine,1996(0):387-400.

[80] Fassbender K;Simons M;Bergmann C;Stroick M;Lutjohann D;Keller P;Runz H;Kuhl S;Bertsch T;von-Bergmann K;Hennerici M;Beyreuther K;Hartmann T .Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo.[J].Proceedings of the National Academy of Sciences of the United States of America,2001(10):5856-5861.

[81] Simons M;Keller P;De-Strooper B;Beyreuther K;Dotti CG;Simons K .Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons.[J].Proceedings of the National Academy of Sciences of the United States of America,1998(11):6460-6464.

[83] Zha Q;Ruan Y;Hartmann T;Beyreuther K;Zhang D .GM1 ganglioside regulates the proteolysis of amyloid precursor protein.[J].Molecular psychiatry,2004(10):946-952.

[85] Sun Y;Yao J;Kim TW;Tall AR .Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion.[J].The Journal of biological chemistry,2003(30):27688-27694.

[86] Hirsch-Reinshagen V;Maia LF;Burgess BL;Blain JF;Naus KE;McIsaac SA;Parkinson PF;Chan JY;Tansley GH;Hayden MR .The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease[J].The Journal of biological chemistry,2005(52):43243-43256.

[87] Hirsch-Reinshagen V;Donkin J;Stukas S;Chan J;Wilkinson A;Fan J;Parks JS;Kuivenhoven JA;Lutjohann D;Pritchard H;Wellington CL .LCAT synthesized by primary astrocytes esterifies cholesterol on glia-derived lipoproteins.[J].Journal of Lipid Research,2009(5):885-893.

[88] Yanagisawa K .Cholesterol and amyloid beta fibrillogenesis.[J].Sub-cellular biochemistry,2005(0):179-202.

[89] Kakio A;Nishimoto SI;Yanagisawa K;Kozutsumi Y;Matsuzaki K .Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid.[J].The Journal of biological chemistry,2001(27):24985-24990.

[90] Amtul Z;Westaway D;Cechetto DF;Rozmahel RF .Oleic acid ameliorates amyloidosis in cellular and mouse models of Alzheimer's disease.[J].Brain pathology,2011(3):321-329.

[92] Puglielli L;Konopka G;Pack-Chung E;Ingano LA;Berezovska O;Hyman BT;Chang TY;Tanzi RE;Kovacs DM .Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide.[J].Nature cell biology,2001(10):905-912.

[93] Hutter Paier B;Huttunen HJ;Puglielli L;Eckman CB;Kim DY;Hofmeister A;Moir RD;Domnitz SB;Frosch MP;Windisch M;Kovacs DM .The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease.[J].Neuron,2004(2):227-238.

[94] Leila A Shobab;Ging-Yuek R Hsiung;Howard H Feldman .Cholesterol in Alzheimer's disease[J].The Lancet,2005(12):841-852.

[95] Bjorkhem I;Cedazo Minguez A;Leoni V .Oxysterols and neurodegenerative diseases.[J].Molecular Aspects of Medicine: An Interdisciplinary Review Journal,2009(3):171-179.

[96] Bjorkhem I .Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain.[J].Journal of Internal Medicine,2006(6):493-508.

[97] Lutjohann D;Papassotiropoulos A;Bjorkhem I;Locatelli S;Bagli M;Oehring RD;Schlegel U;Jessen F;Rao ML;von Bergmann-K;Heun R .Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients.[J].Journal of Lipid Research,2000(2):195-198.

[98] Kolsch H;Heun R;Kerksiek A;Bergmann KV;Maier W;Lutjohann D .Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients.[J].Neuroscience Letters: An International Multidisciplinary Journal Devoted to the Rapid Publication of Basic Research in the Brain Sciences,2004(3):303-308.

[99] Khandelwal PJ;Herman AM;Moussa CE .Inflammation in the early stages of neurodegenerative pathology.[J].Journal of Neuroimmunology: Official Bulletin of the Research Committee on Neuroimmunology of the World Federation of Neurology,2011(1/2):1-11.

[100] Fan QW;Yu W;Senda T;Yanagisawa K;Michikawa M .Cholesterol-dependent modulation of tau phosphorylation in cultured neurons.[J].Journal of Neurochemistry: Offical Journal of the International Society for Neurochemistry,2001(2):391-400.

[101] Glockner F;Meske V;Lutjohann D;Ohm TG .Dietary cholesterol and its effect on tau protein: a study in apolipoprotein E-deficient and P301L human tau mice.[J].Journal of Neuropathology and Experimental Neurology: Official Journal of the American Association of Neuropathologists, Inc,2011(4):292-301.

[103] Sawamura N;Gong JS;Chang TY;Yanagisawa K;Michikawa M .Promotion of tau phosphorylation by MAP kinase Erk1/2 is accompanied by reduced cholesterol level in detergent-insoluble membrane fraction in Niemann-Pick C1-deficient cells.[J].Journal of Neurochemistry: Offical Journal of the International Society for Neurochemistry,2003(5):1086-1096.

[104] Bu B;Li J;Davies P;Vincent I .Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model.[J].The Journal of Neuroscience: The Official Journal of the Society for Neuroscience,2002(15):6515-6525.

[105] Amtul Z;Uhrig M;Rozmahel RF;Beyreuther K .Structural insight into the differential effects of omega-3 and omega-6 fatty acids on the production of Abeta peptides and amyloid plaques.[J].The Journal of biological chemistry,2011(8):6100-6107.

[106] Endogenous conversion of omega-6 into omega-3 fatty acids improves neuropathology in an animal model of Alzheimer's disease[J].Journal of Alzheimer's disease: JAD,2011(4):853-869.

[107] Martin V;Fabelo N;Santpere .Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex.[J].Journal of Alzheimer's disease,2010(2):489-502.

[108] Fraser T;Tayler H;Love S .Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer's disease.[J].Neurochemical research,2010(3):503-513.

[109] Han X;M Holtzman D;McKeel DW Jr;Kelley J;Morris JC .Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis.[J].Journal of Neurochemistry: Offical Journal of the International Society for Neurochemistry,2002(4):809-818.

[110] Cutler RG;Kelly J;Storie K;Pedersen WA;Tammara A;Hatanpaa K .Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease[J].Proceedings of the National Academy of Sciences of the United States of America,2004(7):2070-2075.

[111] He X;Huang Y;Li .Deregulation of sphingolipid metabolism in Alzheimer's disease.[J].Neurobiology of Aging: Experimental and Clinical Research,2010(3):398-408.

[113] Hejazi, Leila;Wong, Jason W. H.;Cheng, Danni;Proschogo, Nicholas;Ebrahimi, Diako;Garner, Brett;Don, Anthony S. . .Mass and relative elution time profiling: two-dimensional analysis of sphingolipids in Alzheimer's disease brains[J].The Biochemical Journal,2011(1):165-175.

[115] Patil S;Melrose J;Chan C .Involvement of astroglial ceramide in palmitic acid-induced Alzheimer-like changes in primary neurons.[J].The European Journal of Neuroscience,2007(8):2131-2141.

[116] Puglielli L;Ellis BC;Saunders AJ;Kovacs DM .Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis.[J].The Journal of biological chemistry,2003(22):19777-19783.

[121] Han X;Cheng H;Fryer JD;Fagan AM;Holtzman DM .Novel role for apolipoprotein E in the central nervous system. Modulation of sulfatide content.[J].The Journal of biological chemistry,2003(10):8043-8051.

[122] Yuki D;Sugiura Y;Zaima N;Akatsu H;Hashizume Y;Yamamoto T;Fujiwara M;Sugiyama K;Setou M.Hydroxylated and non-hydroxylated sulfatide are distinctly distributed in the human cerebral cortex.[J].Neuroscience: An International Journal under the Editorial Direction of IBRO,2011:44-53.

[124] Li,H.;Evin,G.;Hill,A.F.;Hung,Y.H.;Bush,A.I.;Garner,B. .Dissociation of ERK signalling inhibition from the anti-amyloidogenic action of synthetic ceramide analogues[J].Clinical Science,2012(9/10):409-419.

[126] Hagen N;Hans M;Hartmann D;Swandulla D;van Echten Deckert G .Sphingosine-1-phosphate links glycosphingolipid metabolism to neurodegeneration via a calpain-mediated mechanism.[J].Cell death and differentiation,2011(8):1356-1365.

[127] Geekiyanage,H.;Upadhye,A.;Chan,C. .Inhibition of serine palmitoyltransferase reduces Aβ and tau hyperphosphorylation in a murine model: a safe therapeutic strategy for Alzheimer's disease[J].Neurobiology of Aging: Experimental and Clinical Research,2013(8):2037-2051.

[129] Mulder C;Wahlund LO;Teerlink T;Blomberg M;Veerhuis R;Van Kamp GJ;Scheltens P;Scheffer PG .Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease.[J].Journal of neural transmission,2003(8):949-955.

[133] Guan Z;Wang Y;Cairns NJ;Lantos PL;Dallner G;Sindelar PJ .Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease.[J].Journal of Neuropathology and Experimental Neurology: Official Journal of the American Association of Neuropathologists, Inc,1999(7):740-747.

[134] Igarashi M;Ma K;Gao F;Kim HW;Rapoport SI;Rao JS .Disturbed choline plasmalogen and phospholipid Fatty Acid concentrations in Alzheimer's disease prefrontal cortex.[J].Journal of Alzheimer's disease: JAD,2011(3):507-517.

[135] Farooqui AA .Studies on plasmalogen-selective phospholipase A2 in brain.[J].Molecular Neurobiology,2010(2/3):267-273.

[136] Vane JR;Bakhle YS;Botting RM .Cyclooxygenases 1 and 2.[J].Annual Review of Pharmacology and Toxicology,1998(0):97-120.

[138] Pasinetti GM;Aisen PS .Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain.[J].Neuroscience: An International Journal under the Editorial Direction of IBRO,1998(2):319-324.

[139] Qin W;Ho L;Pompl PN;Peng Y;Zhao Z;Xiang Z;Robakis NK;Shioi J;Suh J;Pasinetti GM .Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity.[J].The Journal of biological chemistry,2003(51):50970-50977.

[140] Halliday G;Robinson SR;Shepherd C;Kril J .Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms.[J].Clinical and experimental pharmacology & physiology,2000(1/2):1-8.

[141] Heneka MT;O'Banion MK .Inflammatory processes in Alzheimer's disease.[J].Journal of Neuroimmunology: Official Bulletin of the Research Committee on Neuroimmunology of the World Federation of Neurology,2007(1/2):69-91.

[142] Hong S;Gronert K;Devchand PR;Moussignac RL;Serhan CN .Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation.[J].The Journal of biological chemistry,2003(17):14677-14687.

[143] Marcheselli VL;Hong S;Lukiw WJ;Tian XH;Gronert K;Musto A;Hardy M;Gimenez JM;Chiang N;Serhan CN;Bazan NG .Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression.[J].The Journal of biological chemistry,2003(44):43807-43817.

[144] Serhan CN;Yang R;Martinod K;Kasuga K;Pillai PS;Porter TF;Oh SF;Spite M .Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions.[J].The Journal of Experimental Medicine,2009(1):15-23.

[145] Lukiw WJ;Cui JG;Marcheselli VL;Bodker M;Botkjaer A;Gotlinger K;Serhan CN;Bazan NG .A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease.[J].The Journal of Clinical Investigation: The Official Journal of the American Society for Clinical Investigation,2005(10):2774-2783.

[147] Bazan NG .Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection.[J].Prostaglandins, Leukotrienes, and Essential Fatty Acids,2009(2/3):205-211.

[150] Ikonomovic MD;Abrahamson EE;Uz T;Manev H;Dekosky ST .Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease.[J].The Journal of Histochemistry and Cytochemistry,2008(12):1065-1073.

[151] Sayas CL;Moreno Flores-MT;Avila J;Wandosell F .The neurite retraction induced by lysophosphatidic acid increases Alzheimer's disease-like Tau phosphorylation.[J].The Journal of biological chemistry,1999(52):37046-37052.

[152] Sayas CL;Avila J;Wandosell F .Regulation of neuronal cytoskeleton by lysophosphatidic acid: role of GSK-3.[J].Biochimica et biophysica acta,2002(1/3):144-153.

[153] Ryan, SD;Whitehead, SN;Swayne, LA;Moffat, TC;Hou, WM;Ethier, M;Bourgeois, AJG;Rashidian, J;Blanchard, AP;Fraser, PE;Park, DS;Figeys, D;Bennett, SAL .Amyloid-beta(42) signals tau hyperphosphorylation and compromises neuronal viability by disrupting alkylacylglycerophosphocholine metabolism[J].Proceedings of the National Academy of Sciences of the United States of America,2009(49):20936-20941.

[155] Gupta VB;Laws SM;Villemagne VL;Ames D;Bush AI;Ellis KA;Lui JK;Masters C;Rowe CC;Szoeke C;Taddei K;Martins RN .Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging.[J].Neurology: Official Journal of the American Academy of Neurology,2011(12):1091-1098.

[157] Chawla A;Boisvert WA;Lee CH;Laffitte BA;Barak Y;Joseph SB;Liao D;Nagy L;Edwards PA;Curtiss LK;Evans RM;Tontonoz P .A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis.[J].Molecular cell,2001(1):161-171.

[158] Riddell DR;Zhou H;Comery TA;Kouranova E;Lo CF;Warwick HK;Ring RH;Kirksey Y;Aschmies S;Xu J .The LXR agonist TO901317 selectively lowers hippocampal A beta 42 and improves memory in the Tg2576 mouse model of Alzheimer's disease[J].Molecular and cellular neurosciences,2007(4):621-628.

[159] Vanmierlo T;Rutten K;Dederen J;Bloks VW;van Vark van der Zee LC;Kuipers F;Kiliaan A;Blokland A;Sijbrands EJ;Steinbusch H;Prickaerts J;Lutjohann D;Mulder M .Liver X receptor activation restores memory in aged AD mice without reducing amyloid.[J].Neurobiology of Aging: Experimental and Clinical Research,2011(7):1262-1272.

[161] Mahley RW;Weisgraber KH;Huang YD .Apolipoprotein E4: A causative factor and therapeutic target in neuropathology including Alzheimer's disease[J].Proceedings of the National Academy of Sciences of the United States of America,2006(15):5644-5651.

[162] Chen,H.-K.;Liu,Z.;Meyer-Franke,A.;Brodbeck,J.;Miranda,R.D.;McGuire,J.G.;Pleiss,M.A.;Ji,Z.-S.;Balestra,M.E.;Walker,D.W.;Xu,Q.;Jeong,D.-E.;Budamagunta,M.S.;Voss,J.C.;Freedman,S.B.;Weisgraber,K.H.;Huang,Y.;Mahley,R.W. .Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons[J].The Journal of biological chemistry,2012(8):5253-5266.

[163] Fonseca AC;Resende R;Oliveira CR;Pereira CM .Cholesterol and statins in Alzheimer's disease: current controversies.[J].Experimental Neurology,2010(2):282-293.

[164] Kandiah N;Feldman HH .Therapeutic potential of statins in Alzheimer's disease.[J].Journal of the Neurological Sciences,2009(1/2):230-234.

[165] Menge T;Hartung HP;Stuve O .Statins - a cure-all for the brain?[J].Nature reviews neuroscience,2005(4):325-331.

[168] Rockwood K;Kirkland S;Hogan DB;MacKnight C;Merry H;Verreault R;Wolfson C;McDowell I .Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.[J].Archives of Neurology,2002(2):223-227.

[169] Rodriguez EG;Dodge HH;Birzescu MA;Stoehr GP;Ganguli M .Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study.[J].Journal of the American Geriatrics Society,2002(11):1852-1856.

[171] Haag MD;Hofman A;Koudstaal PJ;Stricker BH;Breteler MM .Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study.[J].Journal of Neurology, Neurosurgery and Psychiatry,2009(1):13-17.

[172] Piomelli D;Astarita G;Rapaka R .A neuroscientist's guide to lipidomics.[J].Nature reviews neuroscience,2007(10):743-754.

[173] Klose, Christian;Surma, Michal A.;Simons, Kai .Organellar lipidomics - background and perspectives[J].Current Opinion in Cell Biology,2013(4):406-413.


语种: 英文   

基金This review was supported by grants from the National Natu...

  • + 更多
  • 字体大小